Other · developed by Immunocore
IMC-S118AI is an investigational agent studied in type 1 diabetes.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07493122 | Phase 1 | Type 1 Diabetes | Not yet recruiting | IMCR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Diabetes Type 1Type 1 DiabetesType 1 Diabetes (T1D)
Updated Oct 18, 2026. Something wrong or missing? Report it on the IMCR page.
See IMCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMCR catalysts and pipeline →